Syndax Pharmaceuticals
SNDX
8.72
-0.41
-4.49%
Syndax Pharmaceuticals
US · SNDX
#2947 by market cap
Listed 2016
8.72
-0.41
-4.49%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/11/5
-
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire · 2026/11/10
-
Rating change
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $36Market Newswire · 2026/11/3
-
Rating change
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/11/3
-
Company notice
Syndax Pharmaceuticals | 8-K: Syndax Reports Third Quarter 2026 Financial Results and Provides Business UpdateSEC · 2026/11/3
-
Rating change
Syndax Pharmaceuticals Price Target Maintained With a $38.00/Share by HC Wainwright & Co.Dow Jones · 2026/10/13
-
Company notice
Syndax Pharmaceuticals | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Rating change
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $23Market Newswire · 2026/10/13
-
Rating change
UBS Downgrades Syndax Pharmaceuticals(SNDX.US) to Hold Rating, Maintains Target Price $33Market Newswire · 2026/11/3
-
Here's What Analysts Are Forecasting For Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter ResultsSimply Wall St · 2026/11/5
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire · 2026/11/5
-
Rating change
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price TargetBenzinga · 2026/10/13
-
Rating change
Syndax Pharmaceuticals (SNDX) Gets a Buy From BarclaysTipRanks · 2026/10/13
-
Company notice
Syndax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Ondrey AaronSEC · 2026/11/13
-
Rating change
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57Market Newswire · 2026/11/3
-
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/11/5
-
Company notice
Syndax Pharmaceuticals | 10-Q: Quarterly reportSEC · 2026/11/3
-
Rating change
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36Benzinga · 2026/11/3
-
Company notice
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ondrey AaronSEC · 2026/11/13
-
Rating change
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/11/3
-
Syndax Pharmaceuticals Suffers Pipeline BlowBenzinga · 2026/10/14
-
Rating change
H.C. Wainwright Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)TipRanks · 2026/9/22
-
Company notice
10-Q: Syndax Pharmaceuticals | 10-Q: Q2 2026 Earnings ReportSEC · 2026/8/5
-
Rating change
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Pyxis Oncology (PYXS)TipRanks · 2026/10/1
-
Syndax Pharmaceuticals Down Over 17%, On Pace for Largest Percent Decrease Since May 2025 -- Data TalkDow Jones · 2026/10/13
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Syndax Pharmaceuticals discussion 0 comments